Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

A compound represented by the following structural formula:

• or a pharmaceutically acceptable salt, solvate and hydrate thereof, wherein:
• R5 is H, C1-C4 alkyl or aminoalkyl;
• R6 are each, independently, H, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, cycloalkyl, cycloalkyl-C1-C4 alkyl, aryl-C1-C4 alkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthy;
• R7 are each, independently, H, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, cycloalkyl-C1-C4 alkyl, or aryl-C1-C4 alkyl;
• R10 is C1-C10 alkyl, C1-C10 haloalkyl, or a substituted or unsubstituted benzyl;
• and
• R11 are each, independently, halo, hydroxy, carboxy, saturated or unsaturated C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, carbamoyl, dioxaborolan-2-yl, benzoyl, or a substituted or unsubstituted group selected from aryl-C1-C4-alkyl, aryloxy, cycloalkyl, cycloalkyloxy or heterocyclo-oxy.